L Peyrin-Biroulet1, W Sandborn2, B E Sands3, W Reinisch4,5, W Bemelman6, R V Bryant7, G D'Haens8, I Dotan9, M Dubinsky10, B Feagan11, G Fiorino12, R Gearry13, S Krishnareddy14, P L Lakatos15, E V Loftus16, P Marteau17, P Munkholm18, T B Murdoch19, I Ordás20, R Panaccione21, R H Riddell22, J Ruel23, D T Rubin24, M Samaan8, C A Siegel25, M S Silverberg26, J Stoker27, S Schreiber28, S Travis7, G Van Assche29,30, S Danese12, J Panes20, G Bouguen31, S O'Donnell26, B Pariente32, S Winer33, S Hanauer34, J-F Colombel3. 1. INSERM Unité 954 and Department of Hepato-Gastroenterology, University Hospital of Nancy, University of Lorraine, Houdemont, France. 2. Division of Gastroenterology, University of California San Diego, La Jolla, California, USA. 3. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 4. McMaster University, Hamilton, Ontario, Canada. 5. Medical University of Vienna, Vienna, Austria. 6. Department of Surgery, Academic Medical Center, Amsterdam, The Netherlands. 7. Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK. 8. Department of Gastroenterology, Academic Medical Centre, Amsterdam, The Netherlands. 9. Inflammatory Bowel Disease Center, Department of Gastroenterology and Liver Diseases, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 10. Division of Pediatric Gastroenterology and Hepatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 11. University of Western Ontario, London, Ontario, Canada. 12. Inflammatory Bowel Disease Center, Department of Gastroenterology, Humanitas Research Hospital, Rozzano, Milan, Italy. 13. Department of Medicine, University of Otago, Christchurch, New Zealand. 14. Columbia University Division of Digestive and Liver Diseases, New York, New York, USA. 15. First Department of Medicine, Semmelweis University, Budapest, Hungary. 16. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA. 17. AP-HP, Department of Digestive Diseases, Hôpital Lariboisière Medicosurgical and University Denis Diderot, Paris, France. 18. North Zealand Hospital, Capital Region, University of Copenhagen, Copenhagen, Denmark. 19. Inflammatory Bowel Disease Group, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada. 20. Department of Gastroenterology, Hospital Clinic of Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain. 21. Inflammatory Bowel Disease Clinic University of Calgary, Calgary, Alberta, Canada. 22. Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada. 23. Division of Gastroenterology, CHU Sherbrooke, Sherbrooke, Quebec, Canada. 24. Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Medicine, Chicago, Illinois, USA. 25. Dartmouth-Hitchcock Inflammatory Bowel Disease Center, Hanover, New Hampshire, USA. 26. Zane Cohen Centre for Digestive Diseases, Division of Gastroenterology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada. 27. Department of Radiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 28. Department of General Internal Medicine, Christian-Albrechts-University, University Hospital Schleswig Holstein, Kiel, Germany. 29. Division of Gastroenterology, University of Leuven, Leuven, Belgium. 30. University of Toronto, Toronto, Ontario, Canada. 31. Service des Maladies de l'Appareil Digestif et INSERM U991, CHU Pontchaillou et Université de Rennes 1, Rennes, France. 32. Department of Hepato-Gastroenterology, Claude Huriez Hospital, Université Lille Nord de France, Lille, France. 33. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. 34. Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Abstract
OBJECTIVES: The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program was initiated by the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). It examined potential treatment targets for inflammatory bowel disease (IBD) to be used for a "treat-to-target" clinical management strategy using an evidence-based expert consensus process. METHODS: A Steering Committee of 28 IBD specialists developed recommendations based on a systematic literature review and expert opinion. Consensus was gained if ≥75% of participants scored the recommendation as 7-10 on a 10-point rating scale (where 10=agree completely). RESULTS: The group agreed upon 12 recommendations for ulcerative colitis (UC) and Crohn's disease (CD). The agreed target for UC was clinical/patient-reported outcome (PRO) remission (defined as resolution of rectal bleeding and diarrhea/altered bowel habit) and endoscopic remission (defined as a Mayo endoscopic subscore of 0-1). Histological remission was considered as an adjunctive goal. Clinical/PRO remission was also agreed upon as a target for CD and defined as resolution of abdominal pain and diarrhea/altered bowel habit; and endoscopic remission, defined as resolution of ulceration at ileocolonoscopy, or resolution of findings of inflammation on cross-sectional imaging in patients who cannot be adequately assessed with ileocolonoscopy. Biomarker remission (normal C-reactive protein (CRP) and calprotectin) was considered as an adjunctive target. CONCLUSIONS: Evidence- and consensus-based recommendations for selecting the goals for treat-to-target strategies in patients with IBD are made available. Prospective studies are needed to determine how these targets will change disease course and patients' quality of life.
OBJECTIVES: The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program was initiated by the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). It examined potential treatment targets for inflammatory bowel disease (IBD) to be used for a "treat-to-target" clinical management strategy using an evidence-based expert consensus process. METHODS: A Steering Committee of 28 IBD specialists developed recommendations based on a systematic literature review and expert opinion. Consensus was gained if ≥75% of participants scored the recommendation as 7-10 on a 10-point rating scale (where 10=agree completely). RESULTS: The group agreed upon 12 recommendations for ulcerative colitis (UC) and Crohn's disease (CD). The agreed target for UC was clinical/patient-reported outcome (PRO) remission (defined as resolution of rectal bleeding and diarrhea/altered bowel habit) and endoscopic remission (defined as a Mayo endoscopic subscore of 0-1). Histological remission was considered as an adjunctive goal. Clinical/PRO remission was also agreed upon as a target for CD and defined as resolution of abdominal pain and diarrhea/altered bowel habit; and endoscopic remission, defined as resolution of ulceration at ileocolonoscopy, or resolution of findings of inflammation on cross-sectional imaging in patients who cannot be adequately assessed with ileocolonoscopy. Biomarker remission (normal C-reactive protein (CRP) and calprotectin) was considered as an adjunctive target. CONCLUSIONS: Evidence- and consensus-based recommendations for selecting the goals for treat-to-target strategies in patients with IBD are made available. Prospective studies are needed to determine how these targets will change disease course and patients' quality of life.
Authors: Kelvin T Thia; Edward V Loftus; Darrell S Pardi; Sunanda V Kane; William A Faubion; William J Tremaine; Kenneth W Schroeder; Scott W Harmsen; Alan R Zinsmeister; William J Sandborn Journal: Inflamm Bowel Dis Date: 2010-09-27 Impact factor: 5.325
Authors: Simon P L Travis; Dan Schnell; Piotr Krzeski; Maria T Abreu; Douglas G Altman; Jean-Frédéric Colombel; Brian G Feagan; Stephen B Hanauer; Gary R Lichtenstein; Philippe R Marteau; Walter Reinisch; Bruce E Sands; Bruce R Yacyshyn; Patrick Schnell; Christian A Bernhardt; Jean-Yves Mary; William J Sandborn Journal: Gastroenterology Date: 2013-07-25 Impact factor: 22.682
Authors: W A Stack; S D Mann; A J Roy; P Heath; M Sopwith; J Freeman; G Holmes; R Long; A Forbes; M A Kamm Journal: Lancet Date: 1997-02-22 Impact factor: 79.321
Authors: J Panes; Y Bouhnik; W Reinisch; J Stoker; S A Taylor; D C Baumgart; S Danese; S Halligan; B Marincek; C Matos; L Peyrin-Biroulet; J Rimola; G Rogler; G van Assche; S Ardizzone; A Ba-Ssalamah; M A Bali; D Bellini; L Biancone; F Castiglione; R Ehehalt; R Grassi; T Kucharzik; F Maccioni; G Maconi; F Magro; J Martín-Comín; G Morana; D Pendsé; S Sebastian; A Signore; D Tolan; J A Tielbeek; D Weishaupt; B Wiarda; A Laghi Journal: J Crohns Colitis Date: 2013-04-11 Impact factor: 9.071
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: Remo Panaccione; Subrata Ghosh; Stephen Middleton; Juan R Márquez; Boyd B Scott; Laurence Flint; Hubert J F van Hoogstraten; Annie C Chen; Hanzhe Zheng; Silvio Danese; Paul Rutgeerts Journal: Gastroenterology Date: 2014-02 Impact factor: 22.682
Authors: Carl M Schoellhammer; Gregory Y Lauwers; Jeremy A Goettel; Matthias A Oberli; Cody Cleveland; June Y Park; Daniel Minahan; Yiyun Chen; Daniel G Anderson; Ana Jaklenec; Scott B Snapper; Robert Langer; Giovanni Traverso Journal: Gastroenterology Date: 2017-01-11 Impact factor: 22.682
Authors: Parambir S Dulai; Brigid S Boland; Siddharth Singh; Khadija Chaudrey; Jenna L Koliani-Pace; Gursimran Kochhar; Malav P Parikh; Eugenia Shmidt; Justin Hartke; Prianka Chilukuri; Joseph Meserve; Diana Whitehead; Robert Hirten; Adam C Winters; Leah G Katta; Farhad Peerani; Neeraj Narula; Keith Sultan; Arun Swaminath; Matthew Bohm; Dana Lukin; David Hudesman; John T Chang; Jesus Rivera-Nieves; Vipul Jairath; G Y Zou; Brian G Feagan; Bo Shen; Corey A Siegel; Edward V Loftus; Sunanda Kane; Bruce E Sands; Jean-Frederic Colombel; William J Sandborn; Karen Lasch; Charlie Cao Journal: Gastroenterology Date: 2018-05-30 Impact factor: 22.682
Authors: Christopher Ma; Carla Ascoytia; Kelly P McCarrier; Mona Martin; Brian G Feagan; Vipul Jairath Journal: Dig Dis Sci Date: 2018-06-29 Impact factor: 3.199
Authors: Lea K Christiansen; Bobby Lo; Flemming Bendtsen; Ida Vind; Marianne K Vester-Andersen; Johan Burisch Journal: United European Gastroenterol J Date: 2019-05-17 Impact factor: 4.623
Authors: Arun Swaminath; Eric P Berlin; Adam Cheifetz; Ed Hoffenberg; Jami Kinnucan; Laura Wingate; Sarah Buchanan; Nada Zmeter; David T Rubin Journal: Inflamm Bowel Dis Date: 2019-02-21 Impact factor: 5.325
Authors: Christopher Ma; William J Sandborn; Geert R D'Haens; Guangyong Zou; Larry W Stitt; Siddharth Singh; Ashwin N Ananthakrishnan; Parambir S Dulai; Reena Khanna; Vipul Jairath; Brian G Feagan Journal: Clin Gastroenterol Hepatol Date: 2019-09-20 Impact factor: 11.382